1,967 pharmaceutical and medication recalls tracked. Stay informed about FDA drug safety alerts, prescription medications, over-the-counter drugs, and dietary supplements.
Looking for a specific drug? Use the search page to find recalls by medication name, manufacturer, or NDC number.
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
Fagron Compounding Services is recalling 11,680 bags of Vancomycin HCl 1 g in 250 mL 0.9% Sodium Chloride Injection. The recall is nationwide in the United States. The blue break-off part could detach from the administration port, raising sterility concerns. Stop using immediately and contact the provider for guidance.
Fagron Compounding Services recalled 5,140 bags of norepinephrine Bitartrate injection due to lack of sterility assurance. A blue Break-Off-Part could detach from the administration port. The recall covers nationwide distribution in the U.S. Consumers should stop use and contact providers for guidance.
Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port
CGMP Deviations; presence of N-nitroso-Furosemide (NNF) above the recommended intake limit.
Teva-affiliated Clonidine Transdermal System recalls 113,943 cartons after CGMP deviations. Unapproved raw material prompts recall. Stop use immediately and contact Teva or a healthcare provider for guidance.
Amneal Pharmaceuticals is recalling 29,542 bottles of TRAMADOL HYDROCHLORIDE tablets distributed nationwide in the United States. The recall cites a failed impurity specification for N-nitroso-desmethyl-tramadol (NDSRI) at the 24‑month stability interval. Consumers and healthcare providers should stop using the product immediately and contact Amneal for guidance.
CGMP Deviations: use of an unapproved raw material
Teva Pharmaceuticals recalled 124,054 cartons of Clonidine Transdermal System due to CGMP deviations from an unapproved raw material. The recall affects products sold in the United States. Consumers should stop using the product immediately and consult a healthcare provider for guidance.
Subpotent Drug
Subpotent Drug
Subpotent Drug
Teva Pharmaceuticals recalled 21,930 cartons of Octreotide Acetate for Injectable Suspension distributed nationwide in the United States. The recall stems from lack of assurance of sterility identified during an FDA inspection at the contract manufacturer. Healthcare providers and patients should stop using this product immediately and contact Teva or a physician for guidance.
Chiesi USA recalled 7,235 Curosurf vials distributed nationwide to hospitals and clinics. The recall cites a lack of assurance of sterility. Healthcare providers should stop using the product immediately and contact Chiesi USA for guidance.
Straumann USA recalled 13 Custom Abutment Ti RC units distributed worldwide, including the United States and Canada. A TAN material was misidentified as Titanium Ti Gr4 D during manufacturing, causing RC Titanium abutments to be made from TAN material. Clinics and patients should stop using the devices immediately and follow recall instructions from Straumann USA or their healthcare providers.
Straumann USA LLC recalls 7 Custom Abutment AS Ti for Straumann RC. The recall follows a material mix-up during manufacturing. A TAN material bar was incorrectly identified as Titanium Bar Ti Gr4 D, causing RC Titanium abutments to be made with TAN material. Stop using the device and contact Straumann for instructions immediately.
Teva Pharmaceuticals USA recalled 19,869 cartons of Octreotide Acetate for Injectable Suspension nationwide in the United States after FDA inspection flagged lack of assurance of sterility at the contract manufacturer. The FDA cited quality system deficiencies at Pharmathen International S.A. in Greece. Healthcare providers and patients should stop using the product immediately and contact Teva or
Teva Pharmaceuticals recalled 1,897 cartons of Octreotide Acetate for Injectable Suspension distributed nationwide in the USA after an FDA inspection flagged sterility concerns. The recall is due to lack of assurance of sterility from the contract manufacturer. Consumers and healthcare providers should stop using the product immediately and contact Teva for guidance.
Labelling: Illegible label
Xanax XR extended-release alprazolam recall issued March 17, 2026 remains active. Viatris Specialty LLC distributes the drug nationwide in the United States. The issue is failed dissolution specifications. Patients and healthcare providers should stop using the product immediately and follow the recall instructions for guidance.
Receive immediate notifications when medications you care about are recalled. Stay safe with timely FDA drug safety alerts.